Welcome to our dedicated page for Day One Biopharmaceuticals news (Ticker: DAWN), a resource for investors and traders seeking the latest updates and insights on Day One Biopharmaceuticals stock.
The Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) news page on Stock Titan aggregates company announcements, clinical updates, financial results, and corporate developments for this commercial-stage oncology biopharmaceutical company. Day One describes itself as dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, with a strong emphasis on pediatric cancer and rare cancers.
Investors and followers of DAWN can use this news feed to review updates on OJEMDA™ (tovorafenib), Day One’s Type II RAF kinase inhibitor indicated for certain BRAF-altered pediatric low-grade gliomas. Company press releases cover pivotal and follow-up data from the FIREFLY-1 Phase 2 trial, the ongoing FIREFLY-2/LOGGIC Phase 3 trial in front-line pLGG, and regulatory designations such as Breakthrough Therapy, Rare Pediatric Disease, and Orphan Drug status described in Day One’s communications.
The feed also captures financial results and guidance, including OJEMDA net product revenue trends, license revenue from ex-U.S. commercial rights, and reported cash, cash equivalents, and short-term investments. These updates are often accompanied by conference call details and investor presentations referenced in the company’s Form 8-K filings.
Another important category of DAWN news involves pipeline and portfolio developments. This includes progress in the Phase 1a/1b trial of DAY301, a PTK7-targeted antibody-drug conjugate, and the addition of Emi-Le (emiltatug ledadotin), a B7-H4–targeted ADC for adenoid cystic carcinoma, through the acquisition of Mersana Therapeutics. Corporate announcements around this acquisition, as well as participation in industry and investor conferences such as the J.P. Morgan Healthcare Conference and the Piper Sandler Healthcare Conference, are also reflected.
By reviewing this curated stream of official press releases and related disclosures, users can follow how Day One reports clinical milestones, commercial performance for OJEMDA, and strategic decisions that shape its oncology pipeline. Bookmarking the DAWN news page provides a centralized view of these developments as they are released.
Day One Biopharmaceuticals (Nasdaq: DAWN) will present at the 21st Annual Needham Virtual Healthcare Conference on April 13 at 3:45 p.m. ET. The event provides an opportunity for management to discuss the company's advancements in developing targeted therapies for life-threatening diseases, particularly pediatric cancer. A live audio webcast of the presentation will be accessible via the company's website, with an archived replay available for 30 days post-event.
Founded to address unmet needs in pediatric cancer treatment, Day One focuses on innovative cancer drug development.
Day One Biopharmaceuticals (Nasdaq: DAWN) reported its fourth quarter and full year 2021 financial results on March 7, 2022, highlighting significant clinical milestones and financial metrics. The company expects initial data from its pivotal FIREFLY-1 study on DAY101 in pediatric low-grade glioma by June 2022, with topline results anticipated in Q1 2023. With cash reserves of $284.3 million as of December 31, 2021, Day One is well-positioned to fund operations into 2024. R&D expenses rose to $43.6 million for 2021, reflecting investment in clinical trials. Net losses for the year were $72.8 million.
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company, has announced its participation in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 7 at 2:50 p.m. ET. A live audio webcast of the chat will be accessible on the company’s website, with a replay available for 30 days.
The company specializes in targeted therapies for life-threatening diseases, highlighting its lead product candidate, DAY101, which is currently in a pivotal Phase 2 trial for low-grade glioma in younger patients.
On January 5, 2022, Day One Biopharmaceuticals (Nasdaq: DAWN) announced that CEO Dr. Jeremy Bender will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11 at 10:30 a.m. ET. The presentation will be accessible via a live audio webcast on the company's website, with a replay available for 30 days afterwards. Day One is focused on developing targeted therapies for life-threatening diseases, including its lead candidate DAY101, currently in a pivotal Phase 2 trial for pediatric low-grade glioma.
Day One Biopharmaceuticals (Nasdaq: DAWN) has commenced dosing the first patient in a Phase 2 clinical trial evaluating DAY101 as a monotherapy for patients with RAF-altered solid tumors. DAY101 is a pan-RAF kinase inhibitor targeting the MAPK pathway. The multi-center study, FIRELIGHT-1, aims to assess the safety and efficacy of DAY101 with an overall response rate as the primary endpoint. Day One plans to initiate a Phase 1b combination study with its MEK inhibitor, pimasertib, in Q1 2022, while continuing to gather data from a pivotal trial in pediatric low-grade glioma patients.
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company, announced its participation in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. Management will engage in a pre-recorded discussion, available on November 22 at 10:00 a.m. ET. This talk highlights Day One's mission to develop targeted cancer therapies, particularly for pediatric patients. The company’s lead product candidate, DAY101, is currently in a pivotal clinical trial for low-grade glioma. Access the webcasts via the Company's website.
Day One Biopharmaceuticals (Nasdaq: DAWN) reported significant progress in their pivotal Phase 2 FIREFLY-1 trial for DAY101, targeting pediatric low-grade glioma (pLGG). In Q3 2021, they secured Rare Pediatric Disease Designation and strengthened their leadership team. Financial highlights include cash reserves of $297.2 million, allowing operations to continue into H2 2023. R&D and G&A expenses surged to $9.8 million and $9.4 million, respectively, resulting in a net loss of $19.2 million for Q3 2021. Initial clinical data is anticipated in H1 2022.
Day One Biopharmaceuticals (Nasdaq: DAWN) reported a complete response in a pediatric patient with recurrent spindle cell sarcoma treated with DAY101 monotherapy, demonstrating its potential efficacy. This case will be presented at the 2021 Connective Tissue Oncology Society (CTOS) Virtual Annual Meeting from November 10-13, 2021. DAY101, a type II pan-RAF inhibitor, targets key enzymes in the MAPK pathway and has shown good tolerability and encouraging activity in over 250 patients. The FDA has granted Breakthrough Therapy and Rare Pediatric Disease Designation for DAY101.
Day One Biopharmaceuticals (NASDAQ: DAWN) appointed Jaa Roberson as chief people officer to oversee human resources and talent acquisition. Roberson, with 20 years of HR experience in biopharma and health insurance, aims to contribute to the company's growth in targeted cancer therapies. CEO Jeremy Bender expressed confidence in her leadership, aligning with Day One’s mission to address critical unmet needs in cancer drug development, particularly for children. The firm is currently evaluating DAY101 in a pivotal Phase 2 clinical trial for low-grade glioma.
Day One Biopharmaceuticals (Nasdaq: DAWN) has appointed Scott Garland to its board of directors, enhancing its leadership team as it advances its pivotal Phase 2 FIREFLY-1 clinical trial of DAY101 in pediatric patients with progressive low-grade glioma. Garland brings over 30 years of biopharmaceutical experience, having successfully launched multiple therapies. DAY101, an investigational pan-RAF kinase inhibitor, has shown promising results in early trials, including good tolerability and anti-tumor activity. It is designed to target certain cancers, particularly in children.